SCHEMBL7205686

SCHEMBL7205686

O=C(NC(CCCc1ccccc1)CCCc1ccccc1)C1CCCN(C(=O)C2CCCNC2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 5/20 0.50
ITGA2B P08514 5/20 0.50
KDM4E B2RXH2 3/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 4/20 0.46
BLM P54132 1/20 0.46
HPGD P15428 2/20 0.46
NPC1 O15118 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
F2R P25116 1/20 0.43
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PARP1 P09874 1/20 0.41
GHSR Q92847 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1981342 0.88 GHSR (0.47) ITGB3ITGA2BALDH1A1HPGDTSHR
SCHEMBL1978336 0.84 ITGB3 (0.47) ITGB3ITGA2BKDM4EKMT2AALDH1A1
SCHEMBL13938202 0.83 FKBP1A (0.46)
SCHEMBL13938199 0.80 KDM4E (0.50) ITGB3ITGA2BKDM4EKMT2AALDH1A1
SCHEMBL12597632 0.80 KDM4E (0.52) ITGB3ITGA2BKDM4EKMT2AALDH1A1
SCHEMBL13938181 0.79 ALDH1A1 (0.48) ITGB3ITGA2BKDM4EKMT2AALDH1A1
SCHEMBL1979225 0.78 USP30 (0.50) ITGB3ITGA2BKDM4EKMT2AALDH1A1
SCHEMBL13938072 0.77 RAB9A (0.58) ITGB3ITGA2BALDH1A1HPGDRAB9A
SCHEMBL1980094 0.77 GHSR (0.45) ITGB3ITGA2BALDH1A1TSHRHTT
SCHEMBL1986802 0.75 FKBP1A (0.48) KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476680-B2 Substituted heterocyclic compounds for treating multidrug resistance H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2009-01-13 US disclosed
US-7476680-B2 Substituted heterocyclic compounds for treating multidrug resistance H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) 2009-01-13 US disclosed
EP-1326833-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE THE PROCTER & GAMBLE COMPANY (US) 2003-07-16 EP disclosed
WO-2002032869-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR TREATING MULTIDRUG RESISTANCE THE PROCTER & GAMBLE COMPANY (US) 2002-04-25 WO disclosed